Local immunomodulation for cancer therapy: Providing treatment where needed

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer

(2013) Ramon Arens et al.   SEMINARS IN IMMUNOLOGY

Abscopal but desirable

(2012) Guido Kroemer et al.   OncoImmunology

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Natural immunity to cancer in humans

(2010) Gabriela Bindea et al.   CURRENT OPINION IN IMMUNOLOGY

Nanomedicine

(2010) Betty Y.S. Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

(2008) Andrew D. Simmons et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CTLA-4: a key regulatory point in the control of autoimmune disease

(2008) Kenneth J. Scalapino et al.   IMMUNOLOGICAL REVIEWS